

NCI Pediatric CIRB

REVIEWER WORKSHEET

COOPERATIVE GROUP RESPONSE TO CIRB REVIEW

OMB#: 0925 – 0625 Expiry Date: 01/31/2014

Collection of this information is authorized by The Public Health Service Act, Section 411 (42 USC 285a). Rights of your participation in the National Cancer Institute (NCI) Central Institutional Review Board (CIRB) Initiative is protected by The Privacy Act of 1974, as amended. The purpose of the information collection is to conduct reviews of clinical trial studies. Although your participation in NCI-sponsored research and completion of the forms is voluntary, if you wish to participate in the CIRB, you must complete all questions on the form. The information you provide will be combined for all participants and reported as summaries. It will be kept private to the extent provided by law.

NOTIFICATION TO RESPONDENT OF ESTIMATED BURDEN

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0625). Do not return the completed form to this address.

STUDY ID:		
STUDY TITLE:		
NAME OF CIRB REVIEWER:		
DAT	E COMPLETED:	
1.	This Cooperative Group response is in reference to (check one): CIRB Stipulations from Initial Review CIRB Stipulations from Amendment/Revision/Update Review	
2.	CIRB Stipulations from Continuing Review I have reviewed the following documents (check all that apply):	
Σ.	Cooperative Group Response Letter/Memo Revised Protocol Version Revised Cooperative Group Informed Consent Document(s) Revised NCI Adult CIRB Application for Treatment Studies or NCI Adult/Pediatric CIRB Application for Ancillary Studies Summary of CIRB Application Revisions Other (specify):	

Has the Cooperative Group and/or Study Chair adequately addressed the CIRB

stipulations and/or recommendations from the prior CIRB review?

3.

	Yes No
4.	Did the Cooperative Group response include additional changes aside from the CIRB stipulations and/or recommendations?
	Yes (if yes, check all that apply below) No (if no, skip to Question 6)
5.	Do the additional changes alter the risk/benefit ratio to the participants?
	Yes No
6.	Please provide your comments and/or concerns (if any) regarding the Cooperative Group response and revised documentation.
7.	Please provide your recommendation for CIRB action on the Cooperative Group response and revised documentation.